tert-butyl 4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate | 791852-36-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
• 英文别名: tert-butyl 4-(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
• CAS: 791852-36-3
• 化学式: C₁₅H₂₂N₆O₂
• 分子量: 318.379
• InChiKey: GRWQRBQLJPTKMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  99.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 4-amino-1-piperidinium-4-yl-1H-pyrazolo[3,4-d]pyrimidin-2-ium dichloride
  参考文献：
  名称：

  [EN] INHIBITORS OF AKT ACTIVITY
  [FR] INHIBITEURS D'ACTIVITE AKT

  摘要：

  公开号：

  WO2006065601A3
• 作为产物：
  描述：

  tert-butyl 4-(4-chloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 在 氨 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 tert-butyl 4-(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF AKT ACTIVITY
  [FR] INHIBITEURS D'ACTIVITE AKT

  摘要：

  公开号：

  WO2006065601A3

文献信息

• Inhibitors of akt activity
  申请人：Bilodeau T Mark

  公开号：US20070043001A1

  公开（公告）日：2007-02-22

  The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及化合物，其中包含取代的吡啶基团，可抑制Akt蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物和治疗癌症的方法，包括给予本发明化合物的治疗方法。
• Inhibitors of Akt Activity
  申请人：Arruda Jeannie M.

  公开号：US20080287457A1

  公开（公告）日：2008-11-20

  The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.

  本发明涉及含有取代萘啶的化合物，其抑制Akt蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物以及治疗癌症的方法，包括给予本发明化合物的治疗方法。这些取代萘啶与PCT出版物WO2003/086394中报告的其他萘啶相比具有意外的优点，这些意外的优点可能包括增强的细胞效力/溶解度、更大的选择性、增强的药代动力学性质、缺乏非靶标活性等。
• Inhibitors of Akt activity
  申请人：Merck & Co., Inc.

  公开号：US07579355B2

  公开（公告）日：2009-08-25

  The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及一种含有取代吡啶基团的化合物，其抑制Akt（一种丝氨酸/苏氨酸蛋白激酶）的活性。该发明进一步涉及含有本发明化合物的化疗组合物以及治疗癌症的方法，其中包括给予本发明化合物的治疗。
• Small molecule inhibitors of anthrax edema factor
  作者：Guan-Sheng Jiao、Seongjin Kim、Mahtab Moayeri、April Thai、Lynne Cregar-Hernandez、Linda McKasson、Sean O'Malley、Stephen H. Leppla、Alan T. Johnson

  DOI：10.1016/j.bmcl.2017.11.040

  日期：2018.1

  Anthrax is a highly lethal disease caused by the Gram-(+) bacteria Bacillus anthracis. Edema toxin (ET) is a major contributor to the pathogenesis of disease in humans exposed to B. anthracis. ET is a bipartite toxin composed of two proteins secreted by the vegetative bacteria, edema factor (EF) and protective antigen (PA). Our work towards identifying a small molecule inhibitor of anthrax edema factor is the subject of this letter. First we demonstrate that the small molecule probe 50-Fluorosulfonylbenzoyl 50-adenosine (FSBA) reacts irreversibly with EF and blocks enzymatic activity. We then show that the adenosine portion of FSBA can be replaced to provide more drug-like molecules which are up to 1000-fold more potent against EF relative to FSBA, display low cross reactivity when tested against a panel of kinases, and are nanomolar inhibitors of EF in a cell-based assay of cAMP production. (C) 2017 Elsevier Ltd. All rights reserved.
• INHIBITORS OF AKT ACTIVITY
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1622616B1

  公开（公告）日：2011-06-15